Published: Sat, February 27, 2021
Science | By

Common Johnson & Johnson COVID-19 Vaccine Side Effects, According To FDA

Common Johnson & Johnson COVID-19 Vaccine Side Effects, According To FDA

The Food and Drug Administration took another step toward granting emergency use authorization to a third COVID-19 vaccine Wednesday, announcing that a single dose of Johnson & Johnson's vaccine showed 86% efficacy against severe cases of disease in a US trial.

Health Canada approved the AstraZeneca vaccine for use in people 18 and over, expressing confidence it would work for the elderly even though some countries, including France, have authorized it only for use in people under 65, saying there is not enough evidence it works in older adults.

Justin Trudeau said the first half million of those doses should arrive by March.

Canada's top doctor Theresa Tam said nationally there are 964 reported cases of the variant first detected in the United Kingdom, up from 429 reported two weeks ago.

The difference is in where they are manufactured, she said, using the analogy of the same recipe made in two different kitchens. With that announcement, Public Services and Procurement Minister Anita Anand revealed Canada has secured two million doses of the AstraZeneca COVID-19 vaccine.

Trudeau said as vaccinations ramp up across the country, many provinces have expanded the number of health professions able to administer a COVID-19 vaccine, and he asked for dentists, midwives, pharmacy technicians and retired nurses to lend a hand in the rollout. It instead uses a non-replicating cold virus called an adenovirus to stimulate an immune response, preparing the body to fight COVID-19.

Biden administration officials have said the US expects J&J to release 3 million to 4 million shots next week, assuming it's authorized for use. That wasn't the case last fall, when Pfizer and Moderna were wrapping up testing, and it's not clear if their numbers would hold against the most worrisome of those variants.

Health Canada approves third COVID-19 vaccine

AstraZeneca has licensed the manufacture of the vaccine to the Serum Institute of India, which is marketing the vaccine under the name COVISHIELD.

J&J's vaccine protects against the worst effects of COVID-19 after one shot, and it can be stored up to three months at refrigerator temperatures, making it easier to handle than the previous vaccines, which must be frozen.

While J&J is seeking FDA authorization for its single-dose version, the company is also studying whether a second dose boosts protection. But public health officials warned that those gains may be stalling as more variants take root in the U.S.

"While there has been an overall shift towards greater enthusiasm for getting a COVID-19 vaccination, the demographic groups that are the most enthusiastic, most cautious, and most resistant remain similar to those reported in January", the researchers wrote in the report.
More than a third of Black adults and 26% of surveyed Hispanic adults say they want to wait and see, compared to 18% of surveyed White adults.

On Sunday, a CDC panel is expected to meet to recommend how to best prioritize use of the J&J vaccine.

Other parts of the world already are facing which-is-best challenges.

Canadian regulators on Friday authorized AstraZeneca's coronavirus vaccine for all adults.


Like this: